Posted by Michael Wonder on 12 Sep 2022
Vaxxinity initiates rolling submission for UB-612 COVID-19 vaccine with MHRA
12 September 2022 - Vaxxinity today announced that it has initiated a rolling submission to the MHRA in the United Kingdom for conditional marketing authorisation of its UB-612 COVID-19 vaccine as a heterologous boost to authorised primary series vaccines.
UB-612 is currently being assessed in a Phase 3 pivotal trial as a booster vaccine for subjects who have received primary immunisation with mRNA, adenovirus vector, or inactivated virus vaccines.
